Dalcetrapib – restoring belief in modulating CETP as a beneficial mechanism in cardiovascular disease

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.4, 2012-04, pp. : 569-573

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Promise of Cholesteryl Ester Transfer Protein (CETP) Inhibition in the Treatment of Cardiovascular Disease

Current Pharmaceutical Design, Vol. 19, Iss. 17, 2013-05 ,pp. : 3143-3149

Bentham Science Publishers

Access to resources Recommend Favorite

Clopidogrel + aspirin beneficial for cardiovascular disease

Inpharma, Vol. 1, Iss. 1602, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Hypothyroidism and Cardiovascular Disease: Factors, Mechanism and Future Perspectives

Current Medicinal Chemistry, Vol. 20, Iss. 35, 2013-11 ,pp. : 4411-4418

Bentham Science Publishers

Access to resources Recommend Favorite

Calcium-activated potassium channels – a therapeutic target for modulating nitric oxide in cardiovascular disease?

By Dalsgaard Thomas Kroigaard Christel Simonsen Ulf

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 8, 2010-08 ,pp. : 825-837

Informa Healthcare

Access to resources Recommend Favorite

Modulating the Hypoxia-Inducible Factor Signaling Pathway: Applications From Cardiovascular Disease to Cancer

Current Pharmaceutical Design, Vol. 10, Iss. 8, 2004-03 ,pp. : 821-833

Bentham Science Publishers

Access to resources Recommend Favorite